Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 967 | 161 | 790 |
| Samples | 331 | 78 | 245 |
| Peptides | 284 | 57 | 225 |
Function
EXOC6 · Exocyst complex component 6
The protein encoded by this gene is highly similar to the Saccharomyces cerevisiae SEC15 gene product, which is essential for vesicular traffic from the Golgi apparatus to the cell surface in yeast. It is one of the components of a multiprotein complex required for exocytosis. The 5' portion of this gene and two neighboring cytochrome p450 genes are included in a deletion that results in an autosomal-dominant form of nonsyndromic optic nerve aplasia (ONA). Alternative splicing and the use of alternative promoters results in multiple transcript variants. A paralogous gene encoding a similar protein is present on chromosome 2. [provided by RefSeq, Jan 2016].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 255 amino-acid changes on canonical ENST00000260762 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in EXOC6 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in EXOC6 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 25/612 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Retinoblastoma | 1/27 4% | 0/30 0% |
| Germ Cell Tumour | 2/25 8% | 1/169 1% |
| Colorectal Carcinoma | 11/143 8% | 38/3239 1% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 13/1390 1% |
| Cervical Carcinoma | 1/35 3% | 5/422 1% |
| Melanoma | 1/210 0% | 25/1899 1% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 7/810 1% |
| Bladder Carcinoma | 2/58 3% | 9/956 1% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 16/1592 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Neuroendocrine Tumour | 6/154 4% | 0/577 0% |
| Other Solid Cancers | 0/94 0% | 13/1515 1% |
| Gastric Carcinoma | 0/74 0% | 14/1809 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Ovarian Carcinoma | 4/109 4% | 4/998 0% |
| Medulloblastoma | 0/0 0% | 3/450 1% |
| Small Cell Lung Carcinoma | 4/9 44% | 1/752 0% |
| Other Sarcomas | 1/69 1% | 4/699 1% |
| Non-Cancerous | 1/104 1% | 5/830 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Head and Neck Carcinoma | 2/85 2% | 6/1574 0% |
| Pancreatic Carcinoma | 2/89 2% | 6/1611 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Kidney Carcinoma | 3/85 4% | 6/1862 0% |
| Biliary Tract Carcinoma | 3/54 6% | 1/950 0% |
Mutation Distribution
Where EXOC6 is mutated · all tissues, split by cell line vs tissue
How many mutations in EXOC6 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 967 mutations in EXOC6
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|